We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00537901
First Posted: October 2, 2007
Last Update Posted: December 17, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Dr. Naeem A. Chaudhri, King Faisal Specialist Hospital & Research Center
  Purpose
First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum

Condition Intervention
Colonic Neoplasms Rectal Neoplasms Radiation: First-Line Bevacizumab and Chemotherapy Drug: Bevacizumab

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study

Resource links provided by NLM:


Further study details as provided by Dr. Naeem A. Chaudhri, King Faisal Specialist Hospital & Research Center:

Primary Outcome Measures:
  • Effectiveness [ Time Frame: overall ]

Secondary Outcome Measures:
  • Quality of life [ Time Frame: overall ]

Enrollment: 100
Study Start Date: October 2007
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Radiation: First-Line Bevacizumab and Chemotherapy
    Chemotherapy
    Drug: Bevacizumab
    Chemotherapy
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with metastatic cancer of colon or rectum
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00537901


Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Investigators
Principal Investigator: Shouki Bazarbashi, MD KFSH & RC
  More Information

Responsible Party: Dr. Naeem A. Chaudhri, Principal Investigator, King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier: NCT00537901     History of Changes
Other Study ID Numbers: RAC #2041-082
First Submitted: October 1, 2007
First Posted: October 2, 2007
Last Update Posted: December 17, 2015
Last Verified: December 2015

Keywords provided by Dr. Naeem A. Chaudhri, King Faisal Specialist Hospital & Research Center:
Colon and Rectum Cancer

Additional relevant MeSH terms:
Colonic Neoplasms
Neoplasms
Neoplasm Metastasis
Rectal Neoplasms
Neoplastic Processes
Pathologic Processes
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Colonic Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents